Biotech News

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (ALNY)Alnylam Pharmaceuticals, Inc.2026-07-09 18:25 ESTConference / presentation

May 07, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2026-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada

Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida.

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events . Replays will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X , LinkedIn , Facebook , Instagram , or YouTube .

View source version on businesswire.com : https://www.businesswire.com/news/home/20260507963806/en/

Alnylam Pharmaceuticals, Inc. Christine Akinc

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

Open original release

Related news

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is an RNA medicines company focused on gene-silencing therapeutics across rare and specialty diseases. Investors watch platform execution, label expansion, and how new programs broaden the franchise.

Recent company news

Stock data

Close
288.06 USD
Market cap
39.89B USD
Exchange
NASDAQ
Sector
Biotechnology
Location
United States